6533b85bfe1ef96bd12babfa

RESEARCH PRODUCT

Th17 skewing in the GALT of a Crohn disease patient upon Lactobacillus rhamnosus GG consumption.

Carmelo BudaStefania CampanaAntonio CascioGuido FerlazzoDaniela OliveriIrene BonaccorsiClaudia De Pasquale

subject

0301 basic medicineSettore MED/17 - Malattie InfettiveImmunologyBioinformaticsPeyer's PatcheProbioticInflammatory bowel diseaseTh17 Cell03 medical and health sciencesPeyer's Patches0302 clinical medicineLactobacillus rhamnosusCrohn DiseaseIntestinal mucosaImmunology and AllergyMedicineHumansConsumption (economics)Settore MED/04 - Patologia Generalebiologybusiness.industryCrohn diseaseLacticaseibacillus rhamnosusInflammatory bowel disease; Intestinal mucosa; Lactobacillus rhamnosus; Mucosal barrier; Probiotics; T cell polarizationProbioticsbiology.organism_classificationMucosal barrierT cell polarization030104 developmental biology030220 oncology & carcinogenesisImmunologyTh17 CellsLactobacillus rhamnosubusinessHuman

description

We wish to report on a recent observation we made and that might represent a useful hint for the employment of the so called probiotics in the management of some pathological immune reactions of the gut. By analyzing GALT-associated T cells upon consumption of L. rhamnosus-GG, we obtained some hints that probiotics might have locoregional immunological effects mainly when administered in patients with IBDs rather than in individuals with non-inflamed gut mucosa.

yearjournalcountryeditionlanguage
2015-01-01Immunology letters
10.1016/j.imlet.2015.11.008https://pubmed.ncbi.nlm.nih.gov/26597611